Pharma BD Deal Intelligence

Valeant Pharmaceuticals International, Inc. / PreCision Dermatology, Inc.

2014 · Acquisition/Merger · $475M · Complete

Announcement Sentiment

Skeptical

Valeant closed its acquisition of privately held PreCision Dermatology for $475M cash, expanding its dermatology franchise (already enlarged by Bausch + Lomb). Notable as one of Valeant's bolt-ons during the Allergan hostile-bid period.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Assets Stalled

Assessment window: 5yr post-close.

Key facts

Announced Jul 08, 2014
Closed Jul 08, 2014
Deal value $475M
Deal type Acquisition/Merger
Therapeutic area Dermatology
Indications Dermatology
Key assets Locoid Lipocream, Aldoxorubicin (now sold separately), dermatology portfolio
Mechanism Mixed (topical corticosteroids, retinoids, antifungals)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals